SAR191801CAS# 1234708-04-3 |
2D Structure
- Saquinavir
Catalog No.:BCC1921
CAS No.:127779-20-8
- Ritonavir
Catalog No.:BCC3620
CAS No.:155213-67-5
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Tipranavir
Catalog No.:BCC2002
CAS No.:174484-41-4
- Lopinavir
Catalog No.:BCC3621
CAS No.:192725-17-0
- Darunavir
Catalog No.:BCC3623
CAS No.:206361-99-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1234708-04-3 | SDF | Download SDF |
PubChem ID | 46700750 | Appearance | Powder |
Formula | C22H20N6O3 | M.Wt | 416.43 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 30 mg/mL (72.04 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[[3-[5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-2-pyridin-2-ylpyrimidine-5-carboxamide | ||
SMILES | CC(C)(C1=NC(=NO1)C2=CC(=CC=C2)CNC(=O)C3=CN=C(N=C3)C4=CC=CC=N4)O | ||
Standard InChIKey | VJCLAPUACUQZOV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H20N6O3/c1-22(2,30)21-27-18(28-31-21)15-7-5-6-14(10-15)11-26-20(29)16-12-24-19(25-13-16)17-8-3-4-9-23-17/h3-10,12-13,30H,11H2,1-2H3,(H,26,29) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
SAR191801 Dilution Calculator
SAR191801 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4014 mL | 12.0068 mL | 24.0136 mL | 48.0273 mL | 60.0341 mL |
5 mM | 0.4803 mL | 2.4014 mL | 4.8027 mL | 9.6055 mL | 12.0068 mL |
10 mM | 0.2401 mL | 1.2007 mL | 2.4014 mL | 4.8027 mL | 6.0034 mL |
50 mM | 0.048 mL | 0.2401 mL | 0.4803 mL | 0.9605 mL | 1.2007 mL |
100 mM | 0.024 mL | 0.1201 mL | 0.2401 mL | 0.4803 mL | 0.6003 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay. IC50 value: 12 nM Target: hPGDS The detailed information please refer to WO2011044307A1 and WO2010080563A2
References:
[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.
[2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.
[3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 19
- LY2608204
Catalog No.:BCC4969
CAS No.:1234703-40-2
- PNU 282987
Catalog No.:BCC7318
CAS No.:123464-89-1
- PM 102
Catalog No.:BCC6105
CAS No.:1234564-95-4
- LRRK2-IN-1
Catalog No.:BCC1706
CAS No.:1234480-84-2
- XMD8-92
Catalog No.:BCC2062
CAS No.:1234480-50-2
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
- Boc-Glu(Ofm)-OH
Catalog No.:BCC3391
CAS No.:123417-18-5
- LY2606368
Catalog No.:BCC4105
CAS No.:1234015-52-1
- Z-Arg-OH
Catalog No.:BCC3060
CAS No.:1234-35-1
- ELR510444
Catalog No.:BCC6418
CAS No.:1233948-35-0
- Methyl 4-caffeoylquinate
Catalog No.:BCN3442
CAS No.:123372-74-7
- CAY10650
Catalog No.:BCC4178
CAS No.:1233706-88-1
- 3-O-Caffeoylquinic acid methyl ester
Catalog No.:BCN3484
CAS No.:123483-19-2
- Demethylmurrayanine
Catalog No.:BCN4721
CAS No.:123497-84-7
- Biperiden HCl
Catalog No.:BCC4565
CAS No.:1235-82-1
- Linderaspirone A
Catalog No.:BCN6122
CAS No.:1235126-46-1
- Azelnidipine
Catalog No.:BCC4400
CAS No.:123524-52-7
- AQ-RA 741
Catalog No.:BCC7314
CAS No.:123548-16-3
- rac BHFF
Catalog No.:BCC7644
CAS No.:123557-91-5
- Peptide YY(3-36), PYY, human
Catalog No.:BCC1041
CAS No.:123583-37-9
- Curcumadionol
Catalog No.:BCN3561
CAS No.:1235984-45-8
- PHP 501 trifluoroacetate
Catalog No.:BCC6193
CAS No.:1236105-75-1
- 740 Y-P
Catalog No.:BCC5861
CAS No.:1236188-16-1
- Clerosterol glucoside
Catalog No.:BCN6123
CAS No.:123621-00-1